4591.T

Aug 24, 2026, 04:02 UTC

Ribomic announced that its domestic Phase 3 clinical trial for an achondroplasia treatment drug has reached the planned number of trial sites, with cumulative 16 institutions now able to enroll patients after obtaining IRB approvals at 6 new facilities.